Fungal Keratitis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Fungal Eye Infection Treatment Market Trends, Growth & Outlook and it is segmented by Route of Administration (Oral, Injection, and Topical), Distribution Channel (Hospitals, Drug Stores and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Fungal Keratitis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Fungal Keratitis Treatment Industry Overview

The Fungal Keratitis Treatment Market is moderately competitive. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc., Leadiant Biosciences, Gilead Biosciences, Inc., Bausch Health, Novo Holdings A/S (Xellia Pharmaceuticals), Alvogen, and Merck & Co. Inc. The companies are evolving through various strategies such as mergers and acquisitions, collaborations, and partnerships, along with investment in research and development activities to secure the position in the competitive market. For instance, in October 2019, Eyevance Pharmaceuticals announced the acquisition of TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and NATACYN (natamycin ophthalmic suspension) 5% from Novartis.

Fungal Keratitis Treatment Market Leaders

  1. Merck & Co. Inc.

  2. Bausch Health

  3. Gilead Biosciences

  4. Pfizer Inc.

  5. Glenmark Pharmaceuticals

  6. *Disclaimer: Major Players sorted in no particular order
Fungal Keratitis Treatment Market Concentration

Fungal Eye Infection Treatment Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?